Tetrahydrocortison | 53-05-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Tetrahydrocortison
• 英文别名: (3alpha)-3,17,21-Trihydroxypregnane-11,20-dione；(3R,17R)-3,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-11-one
• CAS: 53-05-4；516-45-0；547-77-3；7235-42-9；28423-49-6
• 化学式: C₂₁H₃₂O₅
• 分子量: 364.482
• InChiKey: SYGWGHVTLUBCEM-DIRXDLKGSA-N

物化性质

• 熔点：
  190°
• 比旋光度：
  D25 +85.5° (abs ethanol)
• 沸点：
  415.66°C (rough estimate)
• 密度：
  1.0666 (rough estimate)
• 溶解度：
  乙醇（微溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

制备方法与用途

生物活性方面， Tetrahydrocortisone 是一种应激性激素，它是由 5-还原酶将 Cortisone 还原而成的 Cortisone 的尿液代谢产物。

文献信息

• Metabolomics-Based Identification of Disease-Causing Agents
  申请人：Skolnick Jeffrey

  公开号：US20110246081A1

  公开（公告）日：2011-10-06

  A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.
• MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES
  申请人：MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：US20220228190A1

  公开（公告）日：2022-07-21

  The present disclosure relates to compositions and methods for combinatorial assessment of nanoscale droplets, as specifically exemplified by massively parallel assessment of spatially-directed (while agnostic as to precise droplet content) combinations of droplets harboring distinct and independently identifiable microbial types and/or chemical compounds or mixtures. More particularly, the disclosure relates to a platform and methodologies for identifying advantageous (including synergistic, additive, etc.) microbial interactions and/or chemical compound or mixture interactions with microbes in a manner that allows for binary, trinary, etc. combinatorial assessments to be performed across a range of many discrete input types of microbes (e.g., 6-16 or more discrete input microbial types), to an extent capable of approaching comprehensive sampling and measurement of microbial community combinations from a selected panel of microbial inputs, optionally also in the presence of chemical compounds or mixtures (e.g., test compounds or mixtures for antimicrobial effect).
• US6274118B1
  申请人：——

  公开号：US6274118B1

  公开（公告）日：2001-08-14
• US9673030B2
  申请人：——

  公开号：US9673030B2

  公开（公告）日：2017-06-06
• [EN] LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN<br/>[FR] LOCALISATION ET THERAPIE DU CANCER ENDOCRINIEN NON PROSTATIQUE AU MOYEN D'AGENTS DIRIGES CONTRE L'ANTIGENE SPECIFIQUE DE LA PROSTATE
  申请人：NORDION INTERNATIONAL INC.

  公开号：WO1995002424A1

  公开（公告）日：1995-01-26

  (EN) It was discovered that prostate-specific antigen is produced by non-prostatic endocrine cancers. It was further discovered that non-prostatic endocrine cancers with steroid receptors can be stimulated with steroids to cause them to produce PSA either initially or at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by labelled biological binding units which bind to prostate-specific antigen in an imaging procedure, such as, radioimaging or magnetic resonance imaging. Further, the PSA-binding units may be constructed to deliver a toxic agent, such as a radioisotope, toxin or a drug to provide endocrine cancer therapy. Another aspect of the invention is passive immunotherapy against endocrine cancers by treatment with PSA-binding units.(FR) Il a été découvert qu'un antigène spécifique de la prostate (PSA) est produit par des cancers endocriniens non prostatiques. Il a été en outre découvert que des cancers endocriniens non prostatiques à récepteurs stéroïdiens peuvent êtres stimulés au moyen de stéroïdes afin qu'ils produisent le PSA, soit initialement, soit à des taux accrus. Cette invention se rapporte à l'imagerie de cancers endocriniens non prostatiques au moyen d'unités de liaison biologiques marquées qui se lient à l'antigène spécifique de la prostate au cours d'un procédé d'imagerie telle que la radio-imagerie ou l'imagerie par résonance magnétique. En outre, les unités de liaison au PSA peuvent être construites de façon à apporter un agent toxique, tel qu'un radio-isotope, une toxine ou un médicament pour effectuer une thérapie du cancer endocrinien. Un autre aspect de l'invention se rapporte à l'immunothérapie passive contre les cancers endocriniens et comprenant un traitement effectué au moyen d'unités de liaison au PSA.